Cristina L., Specialist doctor at Sant Joan de Déu Hospital Barcelona, shared on LinkedIn:
“Anti-GD2 Immunotherapy in retinoblastoma.
We report two cases of metastatic retinoblastoma in patients unable to complete full-dose chemotherapy due to prior toxicities.
Following treatment with naxitamab, intrathecal topotecan, and reduced-intensity myeloablative chemotherapy, they achieved 4 and 5 years of disease-free survival after metastatic relapse.
Could this combination signal a safer, more effective path forward for high-risk RB patients?”
Authors: Cristina Larrosa, Margarida Simao-Rafael, Noelia Salvador, Juan Pablo Muñoz, Cinzia Lavarino, Guillermo Chantada, Jaume Mora
